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Poster Presentations – Biomarkers S51
After six months: VAS, uCTX-I and uCTX-II. After one year: VAS, uCTX-I,
uCTX-II and radiographs.
Results: After 6 months and 1 year of treatment VAS, uCTX-I and uCTX-
II mean values were signiﬁcantly lower than the baseline. 57 were treated
with GCC and 47 with GC. The group that received GCC showed a similar
VAS mean value after 6 months and 1 year when compared with the group
treated with GC. uCTX-I and uCTX-II mean level was lower in the group
treated with GCC (p< 0.05). Radiological score (Kellgren and Lawrence
summarized score for hands) after 1 year showed a reduced progression
compared to the baseline in the hand osteoarthritis group, especially
after GCC treatment (p< 0.05). Finally, uCTX-I has better correlation with
radiological score and with GC in the EOA subgroup (Pearson index:
R=0.44).
Conclusions: (a) uCTX-I and uCTX-II proved to be useful biomarkers
in OAmonitoring; (b) uCTX-I is better correlated with hand EOA and
could represent a potential further marker to asses the evolution of EOA
bone damage; (c) glucosamine and chondroitinsulphate slow down OA
progression; (d) ﬁnally COLLII could represent a further protective factor
in OA cartilage.
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Purpose: To determine the proﬁle of Coll2−1, Coll2−1NO2 and myeloper-
oxydase (MPO) serum concentrations in experimental knee OA induced
in the dog by transection of the anterior cruciate ligament
Methods: Surgical transection of the ACL of the right knee was performed
on 16 adult crossbred dogs. The dogs were sacriﬁced 8 weeks after
the surgical procedure. Coll2−1, Coll2−1NO2 and MPO were measured
by speciﬁc immunoassays in 16 dogs at baseline and every 2 weeks
during the 8 weeks. The results were expressed as median (range). The
Friedman test estimated the variation for each biomarker every 2 weeks
during the 8 weeks.
Results: Immunostainings with D3 and D37, the antiserum recognizing
Coll2−1 and Coll2−1NO2, respectively, labelled extracellular matrix in the
superﬁcial layer of ﬁbrillated cartilage. After the transection of the ACL,
the concentration of 3 biomarkers increased signiﬁcantly (Friedman test:
Coll2−1, Coll2−1NO2 and MPO: p< 0.001). The concentrations of Coll2−1
and MPO were signiﬁcantly increased at week 2 compared to baseline
[Coll2−1 baseline: 281.57 (131.02–384.67) nM vs Coll2−1 week 2: 345.52
(181.15–589.25) nM (p< 0.01) and MPO baseline: 5.16 (<0.4−14.7) ng/ml
vs MPO week 2: 14.54 (3.28−31.50) ng/ml (p< 0.001)] and remained sta-
ble until week 8 [Coll2−1 week 8: 318.89 (117.95–492.28) nM and MPO
week 8: 11.55 (2.87−42.94) ng/ml]. The Coll2−1NO2 concentration in-
creased signiﬁcantly at weeks 6 and 8 compared to baseline [Coll2−1NO2
baseline: 0.54 (0.29−1.48) nM vs Coll2−1NO2 week 6: 0.64 (0.40−1.9)
nM (p< 0.001) vs week 8: 0.61 (0.37−1.79) nM]. The global macroscopic
score correlated positively with the 8-week changes of Coll2−1 (r = 0.57,
p = 0.02). No similar correlations were found for Coll2−1NO2 and MPO.
Finally, there was a positive correlation between the 4-week changes of
Coll2−1 and Coll2−1NO2 and the microscopic score of cartilage lesion
severity (condyles; Coll2−1: r = 0.56, p = 0.025 and Coll2−1NO2: r = 0.52,
p = 0.049). No similar correlations were found for MPO.
Conclusions: These ﬁndings suggest that Coll2−1 is a relevant marker
for the detection of early structural changes in OA dogs. Interestingly,
MPO and Coll2−1NO2 are increased in OA dogs indicating that an
oxidative stress occurs in this OA model.
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Purpose: Aggrecan proteolysis is an early key event in arthritis releasing
fragments into the synovial ﬂuid (SF). In understanding the mechanisms
of cartilage degradation and identifying OA biomarkers detailed aggrecan
fragment patterns from human joint diseases and disease stages are
helpful. This can be obtained by Western blot analysis. We have analyzed
how different preparation methods for SF aggrecan fragments affect
the puriﬁcation levels, sulfated glycosaminoglycan (sGAG) yields and
Western blot immuno patterns.
Methods: Aggrecan fragments were puriﬁed from a human SF-pool
(n> 100, from OA and knee injuries) by: (1) Dissociative and associa-
tive CsCl density gradient centrifugation collecting D1 and A1 fractions;
(2) Boiling SF and collecting supernatant after centrifugation; (3) Blue
SepharoseTM chromatography at pH 7 collecting the non binding ﬂow-
through; (4) Anion chromatography (Mono-QTM or Q-SepharoseTM) at
pH 5 collecting the 2M or 3M NaCl batch eluates. Puriﬁed aggrecan sam-
ples were deglycosylated, separated by SDS-PAGE, transferred to PVDF
membranes and probed with antibodies against aggrecanase generated
neo-epitopes (ARGS, TEGE, SELE, KEEE and LGQR) or against G1-
and G3-domains. sGAG was analyzed by Alcian Blue precipitation, total
protein by BCA method.
Table 1. Puriﬁcation of aggrecan fragments from a human SF-pool




None SF 100 2−6.6
Boiled SF Supernatant 63 79
Blue Sepharose Flow through 67 28
Blue Sepharose & Mono-Q 3M elute 75 95
Blue Sepharose & Q-Sepharose 2M elute 68 925
Density centrifugation D1 86 5770
A1 92 732
Figure 1. Human synovial ﬂuid aggrecan fragments were puriﬁed by
(1) Blue Sepharose and Q-Sepharose; (2) Blue Sepharose and Mono-Q;
(3) Blue Sepharose; (4) D1 fraction; (5) Boiling SF, and analyzed by anti-
ARGS Western blot.
Results: The sGAG/total protein ratio was used as a measure of pu-
riﬁcation level of sGAG containing aggrecan fragments. The highest
puriﬁcation level was in the D1 fraction (Table 1). Blue Sepharose
or Q-Sepharose methods resulted in low puriﬁcation levels (30−40 mg
sGAG/mg protein), while a combination resulted in 20−30 times higher
puriﬁcation. A1 fraction showed similar puriﬁcation level, while puriﬁcation
with Blue Sepharose combined with Mono-Q, or boiling the SF resulted
in modest puriﬁcation levels (80–100mg sGAG/mg protein). Using the
chromatography and CsCl density centrifugation methods the sGAG
recoveries from SF samples were high, and highest yields were obtained
in D1 and A1 samples.
The Western blot immuno pattern of 2M and 3M eluates of anion
chromatography, exempliﬁed by the ARGS immuno pattern (Fig. 1), was
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similar to the patterns observed in the A1 and D1 samples. The pattern of
the boiled SF supernatant sample was identical to the pattern observed
by the CsCl density gradient puriﬁed samples. Without purifying the ag-
grecan fragments from SF, or using only Blue Sepharose chromatography,
no clear Western blot immunobands were detected.
Conclusions: To reliably detect aggrecan fragments by Western blot the
SF sample needs a puriﬁcation level of approximately 80 mg sGAG/mg
total protein. Puriﬁcation of aggrecan fragments using CsCl density cen-
trifugation from SF is the gold standard. Although anion chromatography
samples have lower sGAG yields compared to the CsCl density samples,
the chromatography method has an advantage in that both low Mw
(e.g. G1-IPEN/TEGE) and high Mw (sGAG containing) fragments can
be analyzed in the same sample. The same advantage is found for the
boiled SF supernatant and in addition this method is quick and easy.
87 BIOMARKERS OF CARTILAGE AND BONE DAMAGE AS A
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Purpose: Biomarkers of bone and cartilage turnover have frequently
been evaluated for joint diseases such as rheumatoid arthritis (RA) and
osteoarthritis (OA). Results have thus fare not been very conclusive.
Some biomarkers such as urinary CTXII and serum COMP appear to
correlate with severity of joint degeneration, whereas other are less
distinctive. Hemophilic arthropathy (HA) is a very progressive joint de-
generation as a result of frequent joint bleeds. From clinical practice it is
concluded that the rate of degeneration exceeds that of OA and RA joints.
This degeneration has characteristics of both inﬂammation mediated (as
seen in RA) and degenerative (as seen in OA) joint disease. Furthermore,
the joint damage is largely restricted to 3 major joints (ankle, knees, and
elbows). Therefore, it might be that this rapidly progressive, localized joint
degeneration can be used for the evaluation and validation of biomarkers
of cartilage and bone turnover. In the present study we therefore investi-
gated whether commercially available biomarkers of cartilage and bone in
blood and/or urine are associated with severity of joint damage in patients
with haemophilic arthropathy.
Methods: Blood and urine were collected from 36 patients suffering from
haemophilia. Urine samples were assessed for the amount of CTX-I
and CTX-II. Serum samples were assessed for the amount of CTX-I,
CTX-II, COMP, C1,2C, C2C, and CS846. Radiographs of ankles, knees
and elbows were scored according to Pettersson, a radiographic joint
score speciﬁc for haemophilic arthropathy based on cartilage and bone
changes.
Results: U-CTX-II (R = 0.39; p = 0.01), C1,2C (R=0.31; p = 0.04) and
CS846 (R=0.31; p = 0.03) showed (marginal) correlations with the Pet-
tersson score. Slightly better correlations were obtained when only nar-
rowing of joint space width (JSW) as one of the items in the Pettersson
score was used. The other biomarkers showed no correlation with the
Pettersson score. Also the bone biomarkers did not correlate with spe-
ciﬁc bone changes. Interestingly, combined indexes of different markers,
based on linear stepwise regression analysis, increased the correlation
signiﬁcantly up to R=0.65; p0.001) for the combination of U-CTX-II,
COMP and CS846.
Conclusions: The present results show that even despite this rapidly
progressive degeneration of 6 large joints, from the individual biomarkers
determined only U-CTX-II, C1,2C and CS846 show correlation with the
severity of arthropathy. Importantly, a relation improved when the markers
were related to the process they are supposed to describe (cartilage
degeneration markers with JSW narrowing). Most important, combination
of markers, signiﬁcantly improve the relation with the radiographically
determined joint degeneration. In general however, it may be concluded
that these markers alone seem not of sufﬁcient value for evaluation of
joint damage yet.
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Purpose: Age-related changes in articular cartilage are likely to play
a role in the aetiology of osteoarthritis (OA). One of the major age-
related changes in cartilage is the accumulation of advanced glycation
endproducts (AGEs). Pentosidine is considered an adequate marker for
the many AGEs formed in vivo. The best way to study the effect of
pentosidine on the development of OA is by taking cartilage biopsy.
However this may interfere with the disease process. Therefore, other
sources need to be found to overcome this problem. Skin and cartilage
pentosidine are highly correlated. However skin is not easily obtained in
daily clinical practice.
We investigated whether urine pentosidine levels can be used as surro-
gate marker for cartilage AGE level.
Methods: Paired skin and urine samples were obtained from a cohort
of 300 patients with knee and/or hip pain being part of the Dutch
CHECK cohort. Since urine pentosidine levels can vary in time due
to diet variation, urine was collected at 2 different time points with
3 month time interval. Pentosidine levels were measured in digested skin
samples and urine by HPLC. As measure of kidney function, an estimation
of the glomerular ﬁltration rate was calculated by using the Cockcroft
Gault formula: [(140 − age)×weight (kg)/(0.81×serum creatinine (mmol/l)]
×0.81 for women only.
Results: Skin and urine pentosidine levels increased linearly with age
(R=0.407, and 0.241 respectively; both, P< 0.001). In literature a good
linear relationship between cartilage and skin pentosidine levels was
found (R=0.486). Urine and skin pentosidine levels showed a much
lower correlation (R=0.229, p< 0.01). However, variation was signiﬁcantly
reduced by using the mean urine pentosidine of 2 time-points and when
urine pentosidine was corrected for kidney function (glomerular ﬁltration
rate); the correlation between urine and skin pentosidine levels increased
signiﬁcantly (R=0.628; p< 0.001).
Conclusions: From this study it appears that urine pentosidine when
corrected for kidney function can be used as marker for cartilage AGE.
Based on this study it is worthwhile to study the predictive value of urine
pentosidine in the development and progression of osteoarthritis.
89 THE IMPORTANCE OF BALANCED CARTILAGE AND BONE
TURNOVER
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Purpose: The pathogenesis of osteoarthritis (OA) likely involves interac-
tions between the bone and cartilage compartments of the joint, resulting
in a least some degree of coupling of these pathological processes.
It is presently debated whether the pathogenesis is initiated in the
bone or cartilage sub-compartments. We investigated cross-sectional
and longitudinal relationships between markers for cartilage and bone
turnover in healthy subjects and subjects with radiographic OA. The
focus was primarily correlations between bone and cartilage markers and
secondarily cartilage loss.
Methods: The 21-month study included 159 subjects prospectively se-
lected as representative for the general population. Radiographs were
acquired in a load-bearing semi-ﬂexed position and the Kellgren and
Lawrence index (KL) was assessed. Bone resorption was measured by
the biochemical marker serum CTX-I (C-terminal telopeptide of collagen
type I) and cartilage degradation by urine CTX-II (collagen type II,
sample acquired as second morning void). The total medial tibial and
femoral cartilage volume was quantiﬁed automatically in a computerized
framework from MRI scans acquired using a Turbo 3D T1 sequence
on a 0.18T Esaote scanner (40º FA, TR 50ms, TE 16ms, scan time
10 minutes, resolution 0.7mm×0.7mm×0.8mm). To ensure a homoge-
neous population, only those over 30 years at were included, resulting
in 145 subjects with age 58±13, BMI 26±4, 48% female, and 25% with
radiographic OA (deﬁned as KL> 1).
Figure 1.
